We are live on
!
Find out more
MWNA
Marshall Wace North America Portfolio holdings
AUM
$23.5B
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+7.23%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17.7B
AUM Growth
-$2.27B
(-11%)
Cap. Flow
-$3.05B
Cap. Flow
% of AUM
-17.25%
Top 10 Holdings %
Top 10 Hldgs %
15.77%
Holding
1,947
New
557
Increased
335
Reduced
444
Closed
606
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$113M |
| 2 |
BERY
Berry Global Group, Inc.
BERY
|
+$106M |
| 3 |
Merck
MRK
|
+$95.9M |
| 4 |
Baidu
BIDU
|
+$85.8M |
| 5 |
IQVIA
IQV
|
+$83.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$229M |
| 2 |
Las Vegas Sands
LVS
|
+$150M |
| 3 |
Alibaba
BABA
|
+$131M |
| 4 |
Citigroup
C
|
+$130M |
| 5 |
Micron Technology
MU
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.85% |
| 2 | Technology | 15.39% |
| 3 | Consumer Discretionary | 13.45% |
| 4 | Industrials | 10.48% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
American Express
AXP
$230B
| $835K | ﹤0.01% |
8,515
-113,758
| -93% | -$11.2M |
|
977
Bio-Rad Laboratories Class A
BIO
$9.42B
| $835K | ﹤0.01% |
2,893
-1,895
| -40% | -$523K |
|
978
Vale
VALE
$62.6B
| $835K | ﹤0.01% |
+65,104
| New | +$889K |
|
|
AVLR
979
DELISTED
Avalara, Inc.
AVLR
| $830K | ﹤0.01% |
+15,557
| New | +$740K |
|
|
OMN
980
DELISTED
OMNOVA Solutions Inc.
OMN
| $825K | ﹤0.01% |
+79,324
| New | +$846K |
|
|
BPMP
981
DELISTED
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
| $824K | ﹤0.01% |
39,276
-255,534
| -87% | -$5.09M |
|
982
Stellantis
STLA
$20.8B
| $823K | ﹤0.01% |
+43,588
| New | +$955K |
|
|
TECX
983
Tectonic Therapeutic
TECX
$606M
| $821K | ﹤0.01% |
+2,397
| New | +$865K |
|
984
nLIGHT
LASR
$3.17B
| $819K | ﹤0.01% |
+24,760
| New | +$832K |
|
|
PVLA
985
Palvella Therapeutics
PVLA
$2.27B
| $816K | ﹤0.01% |
2,011
-2,473
| -55% | -$1.18M |
|
986
Harley-Davidson
HOG
$2.71B
| $813K | ﹤0.01% |
19,314
-157,269
| -89% | -$6.63M |
|
|
QTNT
987
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $813K | ﹤0.01% |
+2,531
| New | +$593K |
|
988
Timken Company
TKR
$9.03B
| $812K | ﹤0.01% |
18,643
-91,690
| -83% | -$4.28M |
|
|
CDK
989
DELISTED
CDK Global, Inc.
CDK
| $812K | ﹤0.01% |
12,497
-385,012
| -97% | -$24.9M |
|
|
SHOE
990
Shoe Station Group
SHOE
$428M
| $804K | ﹤0.01% |
49,550
-99,618
| -67% | -$1.39M |
|
|
CCRN
991
DELISTED
Cross Country Healthcare
CCRN
| $803K | ﹤0.01% |
+71,411
| New | +$852K |
|
992
Kiniksa Pharmaceuticals
KNSA
$5.93B
| $800K | ﹤0.01% |
+46,129
| New | +$835K |
|
|
SMAR
993
DELISTED
Smartsheet Inc.
SMAR
| $796K | ﹤0.01% |
+30,656
| New | +$729K |
|
|
TPCO
994
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $792K | ﹤0.01% |
45,837
-26,285
| -36% | -$458K |
|
995
CareDx
CDNA
$2.42B
| $791K | ﹤0.01% |
64,625
+47,266
| +272% | +$542K |
|
996
Xeris Biopharma Holdings
XERS
$1.45B
| $783K | ﹤0.01% |
+41,266
| New | +$802K |
|
|
CXO
997
DELISTED
CONCHO RESOURCES INC.
CXO
| $781K | ﹤0.01% |
+5,643
| New | +$807K |
|
998
Hasbro
HAS
$13.2B
| $780K | ﹤0.01% |
8,449
-519,865
| -98% | -$45.7M |
|
999
Newmark Group
NMRK
$2.63B
| $775K | ﹤0.01% |
54,462
+33,272
| +157% | +$487K |
|
|
CBLK
1000
DELISTED
Carbon Black, Inc. Common Stock
CBLK
| $775K | ﹤0.01% |
+29,822
| New | +$768K |
|
Similar funds
TGHSA
PAM
HB
MWA
3SCA
HFCIV
DVC
NAM
Marshall Wace North America's Q2 2018 Portfolio in Review
As of Q2 2018, Marshall Wace North America held 1,947 positions worth $17.7B, down 11% from $20B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Marshall Wace North America withdrew a net $3.05B in Q2 2018, closing 606 positions and reducing 444 holdings. Its most notable exit was Time Warner Inc, an estimated $63.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Marshall Wace North America opened a new position in IQVIA worth $83.1M.
- Marshall Wace North America's largest Q2 2018 buy was IQVIA: 832,159 shares worth $83.1M.
- Marshall Wace North America added most to Vertex Pharmaceuticals in Q2 2018, an estimated $113M increase.
- Marshall Wace North America's biggest Q2 2018 reduction was Johnson & Johnson, cutting an estimated $229M.
- Marshall Wace North America fully exited Time Warner Inc in Q2 2018, selling an estimated $63.3M.
- Marshall Wace North America's ten largest holdings make up 16% of its $17.7B portfolio in Q2 2018.
- Marshall Wace North America opened 557 new positions and closed 606 in Q2 2018.
- Marshall Wace North America's portfolio value fell 11% quarter-over-quarter to $17.7B.
Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.